One-year efficacy and safety of everolimus-eluting bioresorbable scaffolds in the setting of acute myocardial infarction.

Yongcheol KimYongcheol Kim Youngkeun AhnYoungkeun AhnChong Jin KimMyeong-Chan ChoAndreas BaumbachBill D GogasSpencer B Kingnull null

Published in: PloS one (2020)

At 1-year follow-up, no differences in the rate of DOCE and device thrombosis were observed between patients with AMI treated with BRS and those treated with DP-EES. Our data suggest that imaging-guided BRS implantation in young patients with low risk profiles could be a reasonable strategy in the setting of AMI.

Keyphrases

acute myocardial infarction
percutaneous coronary intervention
left ventricular
high resolution
pulmonary embolism
electronic health record
newly diagnosed
big data
acute coronary syndrome
heart failure
data analysis
atrial fibrillation
fluorescence imaging